These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 35165859)

  • 1. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
    Wilczyński JR; Nowak M
    Exp Suppl; 2022; 113():1-57. PubMed ID: 35165859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunobiology of cancer immunosurveillance and immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunoediting from immune surveillance to immune escape.
    Kim R; Emi M; Tanabe K
    Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The three Es of cancer immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunoediting: from immunosurveillance to tumor escape.
    Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
    Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host immune response in B-cell lymphomas: friend or foe?
    Juszczyński P; Nowak J; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2008; 56(4):245-55. PubMed ID: 18726146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
    Vesely MD; Schreiber RD
    Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics.
    Najaflou M; Shahgolzari M; Khosroushahi AY; Fiering S
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic escape of immunosurveillance by malignant cell precursors.
    Galassi C; Galluzzi L
    EMBO J; 2023 May; 42(10):e114050. PubMed ID: 37051718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
    Mittal D; Gubin MM; Schreiber RD; Smyth MJ
    Curr Opin Immunol; 2014 Apr; 27():16-25. PubMed ID: 24531241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunoediting and immunosculpting pathways to cancer progression.
    Reiman JM; Kmieciak M; Manjili MH; Knutson KL
    Semin Cancer Biol; 2007 Aug; 17(4):275-87. PubMed ID: 17662614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression.
    Aqbi HF; Wallace M; Sappal S; Payne KK; Manjili MH
    J Leukoc Biol; 2018 Feb; ():. PubMed ID: 29469956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The senescence journey in cancer immunoediting.
    Zingoni A; Antonangeli F; Sozzani S; Santoni A; Cippitelli M; Soriani A
    Mol Cancer; 2024 Apr; 23(1):68. PubMed ID: 38561826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of the cancer immunoediting hypothesis.
    Desai R; Coxon AT; Dunn GP
    Semin Cancer Biol; 2022 Jan; 78():63-77. PubMed ID: 33711414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances of RNA m
    Ma S; Barr T; Yu J
    Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and prospects of immunotherapy as cancer treatment.
    Rescigno M; Avogadri F; Curigliano G
    Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8
    Low JT; Chan MWY; Shen CH; Wei KL
    Mol Biol Rep; 2024 Sep; 51(1):959. PubMed ID: 39230620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Immunoediting in the Era of Immuno-oncology.
    Gubin MM; Vesely MD
    Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
    Mizuno S; Yamaguchi R; Hasegawa T; Hayashi S; Fujita M; Zhang F; Koh Y; Lee SY; Yoon SS; Shimizu E; Komura M; Fujimoto A; Nagai M; Kato M; Liang H; Miyano S; Zhang Z; Nakagawa H; Imoto S
    Sci Rep; 2021 Aug; 11(1):15713. PubMed ID: 34344966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma.
    Wu X; Peng M; Huang B; Zhang H; Wang H; Huang B; Xue Z; Zhang L; Da Y; Yang D; Yao Z; Zhang R
    Cancer Lett; 2013 Oct; 340(1):124-33. PubMed ID: 23920127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.